Axel S Merseburger: OLUMPUS Trial, new non-surgical treatment for patients with low-grade UTUC

We are joined by our Editor-in-Chief for European Oncology & Haematology, Axel S Merseburger, to discuss the recent results of the OLYMPUS trial, an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naïve or recurrent low-grade non-invasive UTUC with at least one measurable papillary tumor located above the ureteropelvic junction.

For further information on this trial, please follow the following links

Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial

OLYMPUS points to kidney-sparing option for low-grade UTUC

Questions

1. Before the approval of mitomycin pyelocalyceal, how was low-grade upper tract urothelial cancer treated, and what are the treatment challenges associated with the upper urinary tract? (0:06)

2. How is the gel administered and what is the treatment regimen? (0:52)

3. Could you tell us about the aims, design and inclusion criteria of the OLYMPUS trial? (1:56)

4. What were the major efficacy and safety findings of this trial? (3:16)

5. What patients are most likely to benefit from this therapy and how might it impact the future of urothelial cancer? (4:10)

 

Axel S Merseburger has no conflicts of interest to declare in relation to this video.

Commissioned, edited and funded by Touch Medical Media

Published: 14 May 2020